BRAF V600E MUTATIONS IN METASTATIC MELANOMA - CASE REPORT
The treatment of metastatic melanoma represents a challenge. Vemurafenib, a selective BRAF kinase inhibitor, is a new medicine against carcinoma. Recently, it has been shown that it raises the survival rate among patients with metastatic melanoma who have BRAFV600mutation. This work will discuss new...
Main Authors: | Ivana Inić, Momcilo Inić, Zorka Inić, Milan Zegarac, Aleksandar Martinović, Miomir Šašić, Miloš Bracanović, Gordana Pupić |
---|---|
Format: | Article |
Language: | English |
Published: |
University in Nis, Faculty of Medicine
2014-09-01
|
Series: | Acta Medica Medianae |
Subjects: | |
Online Access: | http://publisher.medfak.ni.ac.rs/2014-html/3-broj/Ivana%20Inic-BRAF.pdf |
Similar Items
-
Three Cases of Combined Therapy in Primary Breast Lymphoma (PBL) with Successful Outcomes
by: Zorka Inic, et al.
Published: (2013-07-01) -
Three Cases of Combined Therapy in Primary Breast Lymphoma (PBL) with Successful Outcomes
by: Zorka Inic, et al.
Published: (2013-01-01) -
The Prognostic Value of Locoregional Interventions for BRAF V600E Metastatic Colorectal Cancer: A Retrospective Cohort Analysis
by: Liu-Fang Ye, et al.
Published: (2021-08-01) -
Case Report: Rechallenge With BRAF and MEK Inhibitors in Metastatic Melanoma: A Further Therapeutic Option in Salvage Setting?
by: Anna Stagno, et al.
Published: (2021-05-01) -
Clinico-economic analysis of PD-1 inhibitors and combinations of BRAF and MEK inhibitors for the treatment of metastatic melanoma with a BRAF V600 gene mutation
by: D. Yu. Belousov, et al.
Published: (2018-07-01)